Dr. Niederhuber, New Acting Director of NCI, Confronts the Old Problem of an Ever-Declining Institute Budget

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 7
Volume 15
Issue 7

Department of Health and Human Services Secretary Michael Leavitt has appointed John Niederhuber, MD, as the National Cancer Institute's acting director after Andrew C. von Eschenbach, MD, resigned the post he had held for 4.5 years.

BETHESDA, Maryland—Department of Health and Human Services Secretary Michael Leavitt has appointed John Niederhuber, MD, as the National Cancer Institute's acting director after Andrew C. von Eschenbach, MD, resigned the post he had held for 4.5 years.

Dr. Niederhuber, a surgical oncologist and former head of the University of Wisconsin Comprehensive Cancer Center, had served as NCI's chief operating officer since President Bush named Dr. von Eschenbach as acting commissioner of the FDA late last summer. In March, Mr. Bush nominated Dr. von Eschenbach as FDA commissioner. He will continue to serve as acting FDA commissioner pending his confirmation and as a senior advisor to Secretary Leavitt. Dr. Niederhuber, who joined NCI in September 2005 as deputy director of translational and clinical sciences, will lead the Institute until a new director is named.

Although he has a new title, Dr. Niederhuber must still confront the same major problem he has wrestled with since last fall—finding funds to support the Institute's growing research needs at a time of ever-shrinking budgets. The latest assault on the pool of money available to NCI: an unexpected $4 million surcharge levied to cover the rising cost of electricity and other resources needed to run the agency's offices and laboratories.

Since Congress completed the "doubling" of NCI's budget in 2003, which actually increased its appropriations by 80% over 5 years, the agency has received less in actual dollars available to it in each successive year. "You've agonized with us over the flat budgets," Dr. Niederhuber said at a meeting of the National Cancer Advisory Board. He warned that the outlook for fiscal year (FY) 2007 looks equally bleak.

In directing NCI's day-to-day operations, Dr. Niederhuber has experienced the frustrations of trying to maintain the Institute's extramural and intramural research priorities with the shrinking dollars available. "When the budget is flat, it is really a deficit budget because of inflation and what we call the chip-away of our budget," he said. These chip-aways include such things as payments to the National Institutes of Health for research projects that involve two or more institutes and/or centers.

The President's NCI budget request for FY 2007 of $4.8 billion was essentially the same amount as Congress appropriated for FY2006. On June 13, the House Appropriations Committee approved a budget bill that contained almost the exact dollar amount as the President requested and forwarded it to the full House for a vote. "There are some very fine differences but actually, with rounding, they do not even show up," said Susan Erickson, director, NCI's Office of Policy Analysis and Response.

Dr. Niederhuber expressed his personal belief that the FY 2007 budget, as was the case with the current budget, would not be enacted on October 1, the beginning of the federal government's fiscal year. "My anticipation is that we will go on a continuation budget, like we've had in years past, and it will probably be in January or so before a budget is in place," he said.

Nor did he foresee relief in the next few years for NCI's dwindling funds. "The reality is that we are not going to get a huge amount of new money from the federal government into the NIH or NCI budgets," he said.

Related Videos
Positive margin rates have not appeared to improve for patients with cancer undergoing surgical care based on several prior studies.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
A panel of 4 experts on multiple myeloma
Video 1 - 4 KOLs are featured in "Treating Patients Referred to Academic Centers for CAR T"
Video 1 - 4 KOLs are featured in "Identifying Potential Candidates for CAR T-Cell Therapy"
Related Content